Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a significant stock increase, rising over 10% and currently trading at 13.95 HKD with a transaction volume of 32.66 million HKD, following the announcement of its drug application for priority review [1] Group 1: Company Developments - On January 6, the CDE official website indicated that Tongyuan Kang Pharmaceutical's application for Tyrosine Kinase Inhibitor (TY-9591) is proposed for priority review [1] - The drug is intended for first-line treatment in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletions (19DEL) or exon 21 (L858R) substitution mutations, along with central nervous system (CNS) metastases [1] - The company previously garnered significant attention at the World Lung Cancer Conference in September, where it presented key Phase II clinical trial results for TY-9591 targeting brain metastases in non-small cell lung cancer [1]
同源康医药-B最高涨超10% TY-9591片拟纳入优先审评